Liver Transplant Has the Lowest Rejection Rate Among Solid Organs (Besides Cornea)
The liver exhibits unique immunologic privilege among solid organ transplants, demonstrating significantly lower rejection rates than kidney, heart, lung, or pancreas transplants due to its active antibody clearance mechanisms and massive vascular bed that disperses donor-specific antibodies.
Immunologic Mechanisms Underlying Hepatic Privilege
The liver possesses distinct biological properties that confer protection against rejection:
Active antibody clearance: The liver actively secretes class I HLA antigens that bind and clear pre-formed HLA antibodies, providing immunologic protection rather than passive resistance 1.
Massive microvasculature: Compared with renal allografts, the liver possesses roughly 100-fold greater microvasculature, allowing donor-specific antibodies to disperse over a larger vascular bed, lowering local antibody density and reducing graft injury 1.
Antibody sink effect: The massive hepatocyte mass functions as an "antibody sink," absorbing circulating donor-specific antibodies before they can reach and damage graft tissue 1.
Clinical Evidence of Lower Rejection Rates
Comparative Rejection Data
The liver demonstrates superior rejection profiles compared to other solid organs:
Class I antibody protection: Pre-formed class I donor-specific antibodies are largely neutralized by the liver allograft, resulting in effective clearance in most cases 1.
Simultaneous liver-kidney transplant outcomes: The combined procedure markedly lowers the incidence of both T-cell-mediated and antibody-mediated rejection in the kidney component compared with kidney-only transplantation 1.
Reduced immunologic injury: Kidney biopsies from simultaneous liver-kidney transplant recipients show significantly fewer molecular markers of inflammation and T-cell activation than those from kidney-only recipients with comparable immunologic risk 1.
Contrast with Other Organs
Other solid organs demonstrate higher rejection rates:
Kidney transplants: Live-donor kidney transplant recipients experience acute rejection in 44% of cases versus 28% in cadaveric transplants, with rejection remaining a significant concern 2.
Heart and lung: These organs lack the unique immunologic advantages of the liver and demonstrate higher rejection rates in clinical practice 3.
Corneal transplants: While corneal transplants have the lowest rejection rates overall (13% rejection rate at 1 year for penetrating keratoplasty in low-risk conditions), the question specifically asks for organs besides the cornea 4.
Important Caveats and Limitations
Partial Protection Only
The liver's immunologic advantage is not absolute:
Incomplete rejection prevention: Liver-derived protection is partial; it does not completely prevent rejection of a simultaneously transplanted kidney 1.
Class II antibody vulnerability: Protection against class II donor-specific antibodies is limited because class II antigen expression in the liver is minimal unless peri-operative hepatic injury occurs 1.
Persistent rejection risk: Approximately 20% of simultaneous liver-kidney transplant recipients still develop renal allograft rejection, underscoring the limits of hepatic immunoprotection 1.
Clinical Management Implications
Despite lower rejection rates, vigilance remains essential:
Continued immunosuppression: Post-liver transplant management requires immunosuppressive regimens comparable to those used for other organ recipients, because immunologic challenges persist 1.
Antibody monitoring: Persistent post-transplant donor-specific antibodies—especially class II antibodies—are linked to high rates of rejection and graft loss 1.
Rejection still occurs: Approximately 15-30% of liver transplant recipients develop one or more episodes of acute cellular rejection, though most can be successfully treated with increased immunosuppression 5.
Answer to the Question
B. Liver is the correct answer. The liver demonstrates the lowest rejection rate among solid organ transplants (excluding cornea) due to its unique immunologic properties, including active antibody clearance, massive vascular dispersion capacity, and antibody sink function 1. This immunologic privilege translates to clinically superior outcomes with lower rates of both T-cell-mediated and antibody-mediated rejection compared to kidney, heart, lung, or pancreas transplants 1.